Clinical Trial Update: DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating DHA (docosahexaenoic acid) for slowing progression of Alzheimer's disease has completed. The results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• DHA (docosahexaenoic acid) (docosahexaenoic acid)

Snippet

Sponsor: Alzheimer's Disease Cooperative Study (ADCS) | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2010-08-30